MedTrace Logo

The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes

NCT05386186 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2022-05-23

No results posted yet for this study

Summary

The purpose of the trial is to verify the effectiveness and safety of glimepiride compared with sitagliptin as an add-on therapy to metformin in severe insulin deficiency diabetes.

Conditions

  • Diabetes Mellitus, Type 2
  • Severe Insulin Deficient Diabetes

Interventions

DRUG

Glimepiride

Initiate glimepiride 1-4mg once daily as an add-on therapy to metformin and adjust the glimepiride dosage to 1-6 mg once daily in the first 12 weeks according to the diabetes management guideline recommended by the Chinese Diabetes Society.

DRUG

Sitagliptin

Add sitagliptin 100mg once daily in all patients randomized to this arm.

Sponsors & Collaborators

  • Peking University First Hospital

    collaborator OTHER

  • Jiangsu Province Geriatric Institute

    collaborator UNKNOWN

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Xiantong Zou, M.D. Ph.D. · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-10-31
Completion
2024-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05386186 on ClinicalTrials.gov